NCT07355205
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
- Locations
-
- Washington University School of Medicine St Louis, Missouri, United States
Clinical trial condition
Non-small Cell Lung Cancer Stage IV
Explore clinical trials studying Non-small Cell Lung Cancer Stage IV. Study availability and eligibility vary by location and protocol.
17 public trials
5 recruiting studies
Non-small Cell Lung Cancer Stage IV trial results
NCT06463665
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Bronchial Neoplasms, +23 more
- Locations
-
- Pioneer Research Center, LLC Bullhead City, Arizona, United States
- Clermont Oncology Center Clermont, Florida, United States
- Oncology & Hematology Associates of West Broward Coral Springs, Florida, United States
- Helios Clinical Research Fort Lauderdale, Florida, United States
NCT07104630
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
- Locations
-
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
NCT07250477
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
Recruiting
[177Lu]Lu-AKIR001 First-in-human Study
NCT06639191
- Conditions
- Bronchial Neoplasms, Cancer Head and Neck, Carcinoma, +31 more
- Locations
-
- Karolinska University hospital Stockholm, Stockholm County, Sweden
Not Yet Recruiting
Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
NCT06848426
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
- Locations
-
- Jiangxi Provincial People's Hospital Nanchang, Jiangxi, China
Not Yet Recruiting
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC
NCT06436144
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
- Locations
-
Not specified
Not Yet Recruiting
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
NCT06117644
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
- Locations
-
Not specified
NCT04108026
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Besançon - CHU Besançon, France
- Hôpital Ambroise Paré - Pneumologie Boulogne, France
- Caen - CHU Côte de Nacre Caen, France
- CH Colmar, France
Completed
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
NCT03543683
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
- Locations
-
- Daping Hospital Chongqing, Chongqing Municipality, China